Terrance Mcguire Sells 74,764 Shares of Invivyd, Inc. (NASDAQ:IVVD) Stock

Invivyd, Inc. (NASDAQ:IVVD) Director Terrance Mcguire sold 74,764 shares of Invivyd stock in a transaction dated Wednesday, December 18th. The shares were sold at an average price of $0.47, for a total value of $35,139.08. Following the completion of the transaction, the director now owns 3,840,146 shares of the company’s stock, valued at $1,804,868.62. The trade was a 1.91 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Terrance Mcguire also recently made the following trade(s):

• On Monday, December 16th, Terrance Mcguire sold 65,359 shares of Invivyd stock. The shares were sold at an average price of $0.47, for a total transaction of $30,718.73.
• On Wednesday, December 11th, Terrance Mcguire sold 160,400 shares of Invivyd stock. The stock was sold at an average price of $0.59, for a total transaction of $94,636.00.
• On Monday, December 9th, Terrance Mcguire sold 150,000 shares of Invivyd stock. The shares were sold at an average price of $0.61, for a total transaction of $91,500.00.

Invivyd Stock Performance

Shares of IVVD stock opened at $0.43 on Friday. The stock’s 50-day moving average is $0.79 and its two-hundred day moving average is $1.03. Invivyd, Inc. has a 1 year low of $0.43 and a 1 year high of $5.20. The firm has a market cap of $51.40 million, a price-to-earnings ratio of -0.22 and a beta of 0.53.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in IVVD. Proficio Capital Partners LLC purchased a new stake in Invivyd in the third quarter valued at approximately $27,000. SG Americas Securities LLC raised its position in Invivyd by 198.6% in the 2nd quarter. SG Americas Securities LLC now owns 37,893 shares of the company’s stock valued at $42,000 after purchasing an additional 25,201 shares during the last quarter. XTX Topco Ltd boosted its stake in Invivyd by 68.1% during the 2nd quarter. XTX Topco Ltd now owns 37,938 shares of the company’s stock worth $42,000 after purchasing an additional 15,376 shares during the period. Cornercap Investment Counsel Inc. purchased a new position in Invivyd during the 2nd quarter worth $86,000. Finally, Rhumbline Advisers increased its stake in Invivyd by 4,434.1% in the second quarter. Rhumbline Advisers now owns 84,017 shares of the company’s stock valued at $92,000 after purchasing an additional 82,164 shares during the period. Hedge funds and other institutional investors own 70.36% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the company. HC Wainwright dropped their target price on Invivyd from $15.00 to $10.00 and set a “buy” rating on the stock in a report on Wednesday, November 20th. D. Boral Capital reiterated a “buy” rating and issued a $9.00 price objective on shares of Invivyd in a report on Thursday, November 21st. EF Hutton Acquisition Co. I upgraded Invivyd to a “strong-buy” rating in a research note on Wednesday, October 30th. Finally, Morgan Stanley lowered their price target on Invivyd from $9.50 to $3.55 and set an “overweight” rating for the company in a report on Wednesday, November 20th. Four investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Invivyd currently has a consensus rating of “Buy” and an average price target of $7.89.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.